Becton, Dickinson and Company (BDX)

[Enterprising Investor]

Retractable Technologies, Inc. Announces Amended Final Judgment and Notice of Appeal (4/27/15)

LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE MKT: RVP) (“RTI”) announced that on April 23, 2015, the United States District Court for the Eastern District of Texas, Marshall Division, entered an Amended Final Judgment in RTI’s suit against Becton, Dickinson and Company (“BD”) for antitrust and other claims.

The Amended Final Judgment states:

1. BD attempted to monopolize the safety syringe market.

2. BD committed false advertising under the Lanham Act.

3. RTI recovers from BD $340,524,042.00.

4. RTI recovers from BD its attorneys’ fees in the amount of $11,722,823.20.

5. RTI is further awarded post-judgment interest and costs.

6. The Court GRANTS injunctive relief consistent with its prior orders.

On April 24, 2015, BD filed a Notice of Appeal announcing its appeal of the Amended Final Judgment and various other post-trial and post judgment orders to the United States Court of Appeals for the Fifth Circuit.

RTI manufactures and markets VanishPoint® and Patient Safe® safety medical products. The VanishPoint® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. RTI’s products are distributed by various specialty and general line distributors.

For more information on RTI, visit our website at www.vanishpoint.com.

http://www.businesswire.com/news/home/20150427006168/en/Retractable-Technologies-Announces-Amended-Final-Judgment-Notice#.VT6FeIktGUk